Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LYRANASDAQ:OSRHNASDAQ:QTINYSE:RVP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLYRALyra Therapeutics$0.11-1.0%$0.12$0.08▼$0.40$7.40M0.041.91 million shs14.12 million shsOSRHOSR$1.17+2.6%$1.56$1.10▼$13.40$22.55M1.543.25 million shs29,258 shsQTIQT Imaging$0.76-3.8%$0.66$0.35▼$0.92$20.62M-0.2153,218 shs89,273 shsRVPRetractable Technologies$0.72-4.0%$0.72$0.56▼$1.22$21.56M1.6577,312 shs54,964 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLYRALyra Therapeutics0.00%+13.75%+29.13%-46.35%-68.61%OSRHOSR0.00%-6.40%-12.03%+116,999,900.00%+116,999,900.00%QTIQT Imaging-3.80%-11.63%+15.50%+129.61%-12.57%RVPRetractable Technologies0.00%-4.05%+2.71%-9.77%-35.71%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLYRALyra Therapeutics2.0837 of 5 stars3.23.00.00.00.61.71.3OSRHOSRN/AN/AN/AN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLYRALyra Therapeutics 2.33Hold$2.001,690.51% UpsideOSRHOSR 0.00N/AN/AN/AQTIQT Imaging 0.00N/AN/AN/ARVPRetractable Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest LYRA, OSRH, QTI, and RVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$2.00 ➝ $2.00(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLYRALyra Therapeutics$1.19M6.25N/AN/A$1.56 per share0.07OSRHOSR$4.89B0.00N/AN/AN/A∞QTIQT Imaging$4.00M5.16N/AN/A($1.91) per share-0.40RVPRetractable Technologies$33.05M0.65$0.01 per share48.25$3.31 per share0.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLYRALyra Therapeutics-$62.68M-$1.21N/AN/AN/A-6,635.76%-125.07%-59.74%N/AOSRHOSRN/AN/A0.00∞N/AN/AN/AN/AN/AQTIQT Imaging-$4.03MN/A0.00∞N/AN/AN/A-65.94%N/ARVPRetractable Technologies-$7.01M-$0.41N/A∞N/A-41.11%-17.15%-9.33%N/ALatest LYRA, OSRH, QTI, and RVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025LYRALyra Therapeutics-$0.15-$0.12+$0.03-$0.13$0.16 million$0.18 million3/13/2025Q4 2024LYRALyra Therapeutics-$0.12-$0.16-$0.04-$0.16$0.21 million$0.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLYRALyra TherapeuticsN/AN/AN/AN/AN/AOSRHOSRN/AN/AN/AN/AN/AQTIQT ImagingN/AN/AN/AN/AN/ARVPRetractable TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLYRALyra TherapeuticsN/A3.643.64OSRHOSRN/AN/AN/AQTIQT ImagingN/A1.060.48RVPRetractable Technologies0.018.575.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLYRALyra Therapeutics95.62%OSRHOSR55.30%QTIQT Imaging24.19%RVPRetractable Technologies7.58%Insider OwnershipCompanyInsider OwnershipLYRALyra Therapeutics3.25%OSRHOSR33.67%QTIQT Imaging75.40%RVPRetractable Technologies57.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLYRALyra Therapeutics5066.27 million62.39 millionOptionableOSRHOSRN/A19.28 million2.68 millionN/AQTIQT ImagingN/A27.13 million6.68 millionN/ARVPRetractable Technologies24029.94 million13.47 millionOptionableLYRA, OSRH, QTI, and RVP HeadlinesRecent News About These CompaniesThomas J. Shaw Buys 86,014 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 17 at 9:24 AM | insidertrades.comRetractable Technologies (NYSE:RVP) Coverage Initiated at StockNews.comMay 16 at 1:23 AM | americanbankingnews.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025 | RVP Stock NewsMay 15 at 5:47 PM | gurufocus.comRetractable Technologies, Inc. Results for the Period Ended March 31, 2025May 15 at 5:03 PM | businesswire.comRetractable Technologies, Inc. (NYSE:RVP) CEO Buys $10,037.25 in StockMay 15 at 8:43 AM | insidertrades.comStockNews.com Begins Coverage on Retractable Technologies (NYSE:RVP)May 8, 2025 | americanbankingnews.comThomas J. Shaw Purchases 22,620 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockMay 7, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Buys 16,165 Shares of StockApril 24, 2025 | insidertrades.comInsider Buying: Retractable Technologies, Inc. (NYSE:RVP) CEO Purchases 33,524 Shares of StockApril 15, 2025 | insidertrades.comLittle Elm's Retractable Technologies announces 7% workforce reduction due to tariffsApril 11, 2025 | starlocalmedia.comRetractable Technologies cuts workforce to reduce reliance on China amid trade warApril 11, 2025 | drugdeliverybusiness.comRetractable Technologies announces 7% workforce reductionApril 11, 2025 | markets.businessinsider.comRetractable Technologies, Inc. Announces Reduction in WorkforceApril 10, 2025 | businesswire.comRetractable Technologies, Inc. Reports Results for 2024March 28, 2025 | businesswire.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | investing.comRetractable Technologies, Inc. Declares Dividends to Series II and III Class B Preferred Stock ShareholdersMarch 28, 2025 | businesswire.comThomas J. Shaw Buys 18,227 Shares of Retractable Technologies, Inc. (NYSE:RVP) StockFebruary 5, 2025 | insidertrades.comRetractable Technologies CEO Thomas Shaw acquires $14,082 in stockFebruary 4, 2025 | msn.comRetractable Technologies, Inc. (NYSE:RVP) CEO Acquires $10,080.45 in StockJanuary 29, 2025 | insidertrades.comRetractable technologies CEO Thomas Shaw acquires shares worth $10,105January 28, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLYRA, OSRH, QTI, and RVP Company DescriptionsLyra Therapeutics NASDAQ:LYRA$0.11 0.00 (-0.98%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.11 0.00 (-1.52%) As of 05/16/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.OSR NASDAQ:OSRH$1.17 +0.03 (+2.63%) As of 05/16/2025 03:59 PM EasternOSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.QT Imaging NASDAQ:QTI$0.76 -0.03 (-3.80%) As of 05/16/2025QT Imaging Holdings, Inc. engages in the research, development, and commercialization of body imaging systems for detection, diagnosis, monitoring, and treatment of diseases. The company offers QT Ultrasound Breast Scanner, an ultrasonic imaging system that provides reflection-mode and transmission-mode images of a patient's breast. QT Imaging Holdings, Inc. was founded in 2011 and is based in Novato, California.Retractable Technologies NYSE:RVP$0.72 -0.03 (-4.00%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.74 +0.02 (+2.08%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
